Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
49 / 100
AltIndex AI Score
Hold
AI Score · 12-mo trend
−1 pts over 3 months
FundamentalsBullish
TechnicalsNeutral
Alternative dataNeutral
SentimentNeutral
Price$3.84
Year Range$3.48 – $13.48
Market Cap$88M
IndustryBiotechnology

What Is Aardvark Therapeutics’s AI Stock Analysis?

Aardvark Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Aardvark Therapeutics’s momentum in near-real time.

Aardvark Therapeutics (AARD) has an AltIndex AI Score of 49/100, currently a Hold signal. The AI Score distills Aardvark Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.

Aardvark Therapeutics’s Full AI Analysis

Aardvark Therapeutics is a prominent player in the biotechnology sector, focusing on innovative therapeutic solutions. The company has made significant strides in the development of novel drugs and treatments, particularly in niche markets where there is a high unmet medical need. With a robust pipeline and a commitment to R&D, Aardvark Therapeutics is positioned as a key contender in the industry.

Fundamental Analysis

The net income for Aardvark Therapeutics in the last quarter was $14M. This marks a notable increase of 33.36% compared to the previous quarter, indicating solid quarter-over-quarter growth. However, when compared to the same quarter last year, there is a slight decrease of 0.14%, which may raise some concerns about year-over-year growth consistency.

Premium

Keep reading AltIndex’s full AI analysis of Aardvark Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.

Sign up to read the full analysis

What’s Driving AARD’s AI Score?

Fundamentals

Net income for the last quarter was $-14M. This is an increase of -33.36% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 0.14%, which may be a cause for concern. Ebitda for the last quarter was $-14M. This is an increase of -33.32% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 0.22%, which may be a cause for concern.

See Aardvark Therapeutics’s earnings and insider transactions.

Technicals

Today's stock price is $3.84. This represents a decrease of 30.81% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 72.43%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $4.65, which is lower than the previous SMA10 of $4.77. This suggests a potential downward trend in price movement. The RSI is 25.7, indicating a potentially oversold (bullish) condition.

See the full technical analysis and price prediction.

Frequently Asked Questions: Aardvark Therapeutics AI Stock Analysis

Aardvark Therapeutics's AltIndex AI Score is 49/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.

AltIndex's AI Score model rates Aardvark Therapeutics a Hold (49/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.

The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.

AltIndex generates a complete written AI analysis of Aardvark Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the AARD AI Score or sign up to read the full thesis.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.